|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multipotent role of platelets in inflammatory bowel diseases:A clinical approach显示文摘There is evidence that inflammatory bowel diseases(IBD)combine both inflammation and coagulation in their pathogenesis and clinical manifestations.Although platelets(PLT)are well known for their role in hemo stasis,there are a rising number of studies supporting their considerable role as inflammatory amplifiers in chronic inflammatory conditions.IBD are associated with several alterations of PLT,including number shape,and function,and these abnormalities are main ly attributed to the highly activated state of circulating PLT in IBD patients.When PLT activate,they increase in size,release a great variety of bio-active inflamma tory and procoagulant molecules/particles,and express a variety of inflammatory receptors.These inflamma tory products may represent a part of the missing link between coagulation and inflammation,and can be considered as possible IBD pathogenesis instigators.In clinical practice,thrombocytosis is associated both with disease activity and iron deficiency anemia.Controlling inflammation and iron replacement in anemic patient usually leads to a normalization of PLT count.The aim of this review is to update the role of PLT in IBD and present recent data revealing the possible therapeutic implications of anti-PLT agents in future IBD remedies. | Evangelos Voudoukis Konstantinos Karmiris Ioannis E Koutroubakis | 2014 | World Journal of Gastroenterology2014，20，12： | 27 |
| 2 | Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis:A global survey of physicians'practice显示文摘AIM To examine treatment decisions of gastroenterologists regarding the choice of prescribing 5-aminosalycilates(5ASA) with corticosteroids(CS) versus corticosteroids alone for patients with active ulcerative colitis(UC). METHODS A cross-sectional questionnaire exploring physicians' attitude toward 5ASA + CS combination therapy vs CS alone was developed and validated. The questionnaire was distributed to gastroenterology experts in twelve countries in five continents. Respondents' agreement with stated treatment choices were assessed by standardized Likert scale. Background professional characteristics of respondents were analyzed for correlation with responses. RESULTS Six hundred and sixty-four questionnaires were distributed and 349 received(52.6% response rate). Of 340 eligible respondents, 221(65%) would continue 5ASA in a patient hospitalized for intravenous CS treatment due to a moderate-severe UC flare, while 108(32%) would stop the 5ASA(P < 0.001), and 11(3%) are undecided. Similarly, 62% would continue 5ASA in an out-patient starting oral CS. However, only 140/340(41%) would proactively start 5ASA in a hospitalized patient not receiving 5ASA before admission. Most(94%) physicians consider the safety profile of 5ASA as very good. Only 52% consider them inexpensive, 35% perceive them to be expensive and 12% are undecided. On multi-variable analysis, less years of practice and perception of a plausible additive mechanistic effect of 5ASA + CS were positively associated with the decision to continue 5ASA with CS. CONCLUSION Despite the absence of data supporting its benefit, most gastroenterologists endorse combination of 5ASA + CS for patients with active moderate-to-severe UC. Randomized controlled trials are needed to assess if 5ASA confer any benefit for these patients. | Shomron Ben-Horin Jane M Andrews Konstantinos H Katsanos Florian Rieder Flavio Steinwurz Konstantinos Karmiris Jae Hee Cheon Gordon William Moran Monica Cesarini Christian D Stone Doron Schwartz Marijana Protic Xavier Roblin Giulia Roda Min-Hu Chen Ofir Har-Noy Charles N Bernstein | 2017 | World Journal of Gastroenterology2017，23，16： | 3 |
| 3 | Ileal Malignant Melanoma Causing Intussusception: Report of a Case显示文摘 | Konstantinos Karmiris Maria Roussomoustakaki Maria Tzardi John Romanos John Grammatikakis Manolis Papadakis Maria Polychronaki Elias A. Kouroumalis | 2007 | Surgery Today2007，，6： | 2 |
| 4 | Control method evaluation for battery energy storage system utilized in renewable smoothing显示文摘 | KARMIRIS G TENGNER T | 2013 | Industrial Electronics Society2013，10，13： | 1 |
| 5 | Optimising monitoring in the management of Crohn’s disease: A physician’s perspective显示文摘 | Pavol Papay Ana Ignjatovic Konstantinos Karmiris Heda Amarante Pal Milheller Brian Feagan Geert D’Haens Philippe Marteau Walter Reinisch Andreas Sturm Flavio Steinwurz Laurence Egan Julián Panés Edouard Louis Jean-Frédéric Colombel Remo Panaccione | 2013 | Journal of Crohn’s and Colitis2013，，： | 1 |
| 6 | Ileal malignant melanoma causing intussusception: report of a case 显示文摘 | Karmiris K Roussomoustakaki M Tzardi M | 2007 | Surg Today2007，37，6： | 1 |
| 7 | Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease显示文摘 | Evangelos Voudoukis Konstantinos Karmiris Pantelis Oustamanolakis Angeliki Theodoropoulou Aekaterini Sfiridaki Gregorios A. Paspatis Ioannis E. Koutroubakis | 2013 | European Journal of Gastroenterology & Hepatology2013，，10： | 1 |
| 8 | Antibodies against eyclie citrul- linated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations 显示文摘 | Koutroubakis IE Karmiris K Bourikas L | 2007 | Inflammatory Bowel Diseases2007，13，4： | 1 |
| 9 | Partial penile reconstruction following fat augmentation with anterolateral thigh perforator flap显示文摘 | Spyrioumis PK Karmiris NI | 2012 | J Plast Reconstr Aesthet Surg2012，65，： | 1 |
| 10 | Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease 显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2006 | Inflamm Bowel Dis2006，12，2： | 1 |
| 11 | Circulating levels of leptin, adiponeetin, resistin, and ghrelin in inflammatory bowel disease显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2006 | Inflamm Bowel Dis2006，12，2： | 1 |
| 12 | Associa- tion between thrombocytosis and iron deficiency anemia in in- flammatory bowel disease 显示文摘 | Voudoukis E Karmiris K Oustamanolakis P | 2013 | Eur J Gastroenterol Hepatol2013，25，10： | 1 |
| 13 | Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel dis- ease 显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2006 | Inflamm Bowel Dis2006，12，2： | 1 |
| 14 | Serum angiogenin in inflammatory bowel disease显示文摘 | Koutroubakis I E Xidakis C Karmiris K | 2004 | Dig Dis Sci2004，49，1112： | 1 |
| 15 | Circulating levels of lep- tin,adiponectin,resistin and ghrehrt in inflammatory bowel disease显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2006 | Inflamm Bowel Dis2006，12，2： | 1 |
| 16 | Circulating levels of leptin,adiponectin,resistin,and ghrelin in inflammatory bowel disease显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2006 | Inflamm Bowel Dis2006，12，2： | 1 |
| 17 | Partial penile reconstruction following fat augmentation with anterolateral thigh perforator flap 显示文摘 | Spyriounis PK Karmiris NI | 2012 | J Plast Reconstr Aesthet Surg2012，65，1： | 1 |
| 18 | Role of angiogenesis in inflammatory bowel disease 显示文摘 | Koutroubakis IE Tsiolakidou G Karmiris K | 2006 | Inflamm Bowel Dis2006，12，6： | 1 |
| 19 | Pancreatic antoantibodies in greek patients with inflammatory bowel disease 显示文摘 | KOUTROVBAKIS IE DRYQIANNAKJS D KARMIRIS K | 2005 | Dig Dis Sci2005，50，： | 1 |
| 20 | The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with in- flammatory bowel disease显示文摘 | Karmiris K Koutroubakis IE Xidakis C | 2007 | Eur J Gastroenterol Hepato12007，19，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员